BioRestorative Therapies Net Worth
BioRestorative Therapies Net Worth Breakdown | BRTX |
BioRestorative Therapies Net Worth Analysis
BioRestorative Therapies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BioRestorative Therapies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BioRestorative Therapies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BioRestorative Therapies' net worth analysis. One common approach is to calculate BioRestorative Therapies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BioRestorative Therapies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BioRestorative Therapies' net worth. This approach calculates the present value of BioRestorative Therapies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BioRestorative Therapies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BioRestorative Therapies' net worth. This involves comparing BioRestorative Therapies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BioRestorative Therapies' net worth relative to its peers.
Enterprise Value |
|
To determine if BioRestorative Therapies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioRestorative Therapies' net worth research are outlined below:
| BioRestorative Therapies had very high historical volatility over the last 90 days | |
| BioRestorative Therapies may become a speculative penny stock | |
| BioRestorative Therapies has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 145.8 K. Net Loss for the year was (10.42 M) with profit before overhead, payroll, taxes, and interest of 352.27 K. | |
| BioRestorative Therapies currently holds about 17.93 M in cash with (6.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 28.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical ... |
BioRestorative Therapies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioRestorative Therapies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioRestorative Therapies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know BioRestorative Therapies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioRestorative Therapies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioRestorative Therapies backward and forwards among themselves. BioRestorative Therapies' institutional investor refers to the entity that pools money to purchase BioRestorative Therapies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Advisor Group Holdings, Inc. | 2024-12-31 | 193 | |
| Sbi Securities Co Ltd | 2024-12-31 | 60.0 | |
| Bank Of America Corp | 2024-12-31 | 42.0 | |
| Td Waterhouse Canada Inc | 2024-12-31 | 2.0 | |
| Susquehanna International Group, Llp | 2024-12-31 | 0.0 | |
| Wells Fargo & Co | 2024-09-30 | 0.0 | |
| Renaissance Technologies Corp | 2024-12-31 | 0.0 | |
| Geode Capital Management, Llc | 2024-12-31 | 54.7 K | |
| Stonex Group Inc | 2024-12-31 | 50.1 K | |
| Wealth Alliance, Llc | 2024-12-31 | 40 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 27.5 K |
Follow BioRestorative Therapies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.73 M.Market Cap |
|
Project BioRestorative Therapies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (1.75) | (1.66) | |
| Return On Assets | (0.74) | (0.78) | |
| Return On Equity | (1.20) | (1.14) |
When accessing BioRestorative Therapies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BioRestorative Therapies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioRestorative Therapies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioRestorative Therapies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioRestorative Therapies. Check BioRestorative Therapies' Beneish M Score to see the likelihood of BioRestorative Therapies' management manipulating its earnings.
Evaluate BioRestorative Therapies' management efficiency
BioRestorative Therapies has return on total asset (ROA) of (0.5324) % which means that it has lost $0.5324 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8456) %, meaning that it created substantial loss on money invested by shareholders. BioRestorative Therapies' management efficiency ratios could be used to measure how well BioRestorative Therapies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2025. Return On Capital Employed is likely to rise to -1.66 in 2025. At this time, BioRestorative Therapies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 368.6 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 1.3 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.13 | 2.24 | |
| Tangible Book Value Per Share | 1.98 | 2.08 | |
| Enterprise Value Over EBITDA | (0.40) | (0.42) | |
| Price Book Value Ratio | 0.66 | 0.69 | |
| Enterprise Value Multiple | (0.40) | (0.42) | |
| Price Fair Value | 0.66 | 0.69 | |
| Enterprise Value | 7.6 M | 4.5 M |
Understanding the operational decisions made by BioRestorative Therapies management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 0.4923 | Revenue | Quarterly Revenue Growth 6.609 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioRestorative Therapies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioRestorative Therapies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioRestorative Therapies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioRestorative Therapies time-series forecasting models is one of many BioRestorative Therapies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioRestorative Therapies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
BioRestorative Therapies Earnings per Share Projection vs Actual
BioRestorative Therapies Corporate Management
| Francisco Silva | VP Scientist | Profile | |
| Robert Paccasassi | Vice Compliance | Profile | |
| Stephen Kilmer | Investor Officer | Profile | |
| Wayne MD | Clinical Board | Profile | |
| Robert Kristal | Chief Officer | Profile |
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.